Egrifta (Tesamorelin) Indications
Egrifta is FDA-approved specifically for the reduction of excess abdominal fat (visceral adipose tissue) in HIV-infected adult patients with lipodystrophy. 1
Primary Indication
The sole FDA-approved indication is:
- Reduction of excess abdominal fat in HIV-positive adults with lipodystrophy 1
This addresses the central fat accumulation that commonly occurs in HIV-associated lipodystrophy, a condition affecting 25-75% of patients on antiretroviral therapy, particularly those on protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) 2.
Critical Limitations of Use
The FDA label explicitly states several important limitations 1:
- Not indicated for weight loss management - tesamorelin has a weight-neutral effect
- Long-term cardiovascular safety has not been established - clinicians should consider risk/benefit of continuing treatment in patients who have not achieved reduction in visceral adipose tissue
- No data support improved compliance with antiretroviral therapies in HIV-positive patients taking Egrifta
- Consider discontinuation if no reduction in visceral adipose tissue is achieved
Contraindications
Egrifta is absolutely contraindicated in 1:
- Patients with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, head trauma)
- Active malignancy (any preexisting malignancy must be inactive and treatment complete)
- Known hypersensitivity to tesamorelin or excipients
- Pregnant women - modifying visceral adipose tissue offers no benefit during pregnancy and could result in fetal harm
Evidence of Efficacy
The indication is supported by robust clinical trial data showing 3, 4, 5, 6:
- Significant reduction in visceral adipose tissue (mean decrease ~27.71 cm²)
- Reduction in trunk fat (~1.18 kg decrease)
- Decreased waist circumference (~1.61 cm)
- Reduction in hepatic fat percentage (~4.28%)
- Improvements maintained through 52 weeks of treatment
- However, discontinuation results in reaccumulation of visceral fat
Recent data confirm efficacy even in patients on integrase inhibitor-based regimens 7, which are now the mainstay of HIV therapy and are associated with weight gain.
Clinical Context
While the 2002 guidelines noted that "no clearly effective therapy for fat accumulation or lipoatrophy is known" 2, tesamorelin (approved in 2010) now provides the only FDA-approved pharmacological option specifically targeting visceral fat accumulation in HIV-associated lipodystrophy 8. The drug does not significantly affect subcutaneous adipose tissue, which distinguishes it from general weight loss interventions 4, 5.
The decision to use Egrifta should focus on patients with documented excess visceral adipose tissue causing metabolic complications or significant body image distress, understanding that treatment must be continued long-term to maintain benefits.